news11 May 2018 | By European Pharmaceutical Review
A new study found that infections caused by the drug resistant bacteria - methicillin-resistant Staphylococcus aureus, known as MRSA - are no more expensive to treat than MSSA, the methicillin-susceptible version of the same bacteria.